SNMMI president weighs in on Lymphoseek approval

03/17/2013 | DOTMed.com

SNMMI President Frederic H. Fahey said Lymphoseek, recently approved by the FDA to map the spread of cancer, will improve diagnoses. The drug "lets you be more confident that you are taking the correct lymph node out," Fahey said. The agent employs a targeted approach to seek out the sentinel lymph node, and it can stay in place longer, which can be more convenient for patients, Fahey said.

View Full Article in:

DOTMed.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA